Slide 1: LivaNova Investor Day: Cardiac Surgery
LivaNova Investor Day CARDIAC SURGERY Alistair Simpson General Manager, Cardiac Surgery September 14, 2017
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain statements in this presentation, other than purely historical information, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 19
Slide 3: We are a market leader in Cardiac Surgery
We are a market leader in Cardiac Surgery CARDIOPULMONARY HEART VALVES EPILEPSY TREATMENT-RESISTANT DEPRESSION Preferred HLM* by perfusionists, Differentiated in a large, growing fastest oxygenator adoption segment: the only sutureless valve CUSTOMERS DISEASE STATE MARKET Heart valve disease Perfusi
Slide 4: We have a strong core foundation with key growth drivers
We have a strong core foundation with key growth drivers Reduces transfusions and S5® HEART-LUNG MACHINE improves recovery Inspire® Personalized perfusion OXYGENATOR Data drives better outcomes CONNECTTM in clinical efficacy Optimizing the surgical Perceval® SUTURELESS VALVE valve replacement High p
Slide 5: Cardiopulmonary
LY x \ yi, Selig / ’ SN / CARDFOPULMONARY NOS IN f Z Ay / Hi LivaNova
Slide 6: Large market with opportunity to further surround the perfusionist
Large market with opportunity to further surround the perfusionist $2.3B market M&A opportunity Capital Capital 40% LivaNova share M&A Market is growing opportunity low-single digits Disposables M&A enables faster 28% LivaNova share than market / mid- single-digit growth Disposables Estimated total
Slide 7: Our HLM is the market leader
Our HLM is the market leader Reduces transfusions, better neurological protection 70% market share, available in 30 languages Proven safety over 40 years Robust, proven reliability, Near-term: commercial execution and S5 made in Germany enhancements Mid- to long-term: 100% customizable, flexible, ne
Slide 8: Inspire ignited the fastest adoption of oxygenators
Inspire ignited the fastest adoption of oxygenators Reduces transfusions, better neurological protection 30% market share, market leader Broad choice from complete family of products Fastest adoption ever, Near-term: commercial execution and closing in on 1 million patients leverage HLM footprint Mi
Slide 9: CONNECTing the cardiopulmonary workflow
CONNECTing the cardiopulmonary workflow Data is the driver for Goal Directed Perfusion HLM • One system connects data from all devices • Automatic integration S5® of perfusion data, patient parameters and product information • Allows user to tailor OXYGENATOR ATS perfusion to individual patient fact
Slide 10: Investing in the future of cardiopulmonary
Investing in the future of cardiopulmonary LIVANOVA CLINICAL NEEDS SOLUTION • MICS support • Near-term S5 • Data compatibility enhancements with hospital systems • Mid- to long-term • Improved patient next-generation S5 Capital management • Next-generation Connect • M&A capital opportunity • Patient
Slide 11: Heart Valves
Heart Valves LivaNova
Slide 12: Tissue valves will be a larger component of the valve portfolio
Tissue valves will be a larger component of the valve portfolio • Decline in line with market MECHANICAL • Target specific regions • Invest in sutureless fast- deployment valves • Perceval main growth driver TISSUE • Tissue valve growth will outgrow the decline in mechanical in 2018 2017 2022 Source
Slide 13: Perceval: the only sutureless fast-deployment valve in the market
Perceval: the only sutureless fast- deployment valve in the market 10+ years of clinical use/data 190+ publications Enabler for minimally invasive procedures Strong economic benefits Our goal is $80M by 2018 13
Slide 14: Recent studies continue to show clinical and economic benefits of Perceval
Recent studies continue to show clinical and economic benefits of Perceval Comprehensive systematic review of 9 years of studies, reports the following main findings for Perceval: • Simplify surgery by reducing ischemic time in all procedures • Facilitate MICS • Show lower mortality and PVL vs TAVR
Slide 15: Driving expansion and penetration of Perceval
Driving expansion and penetration of Perceval Near-term Medium-term • Focusing on $200M • Larger sizes to increase MICS segment addressable market • Sales force • Continued clinical and effectiveness economic evidence to support efficacy • Proctorship expansion • Geographic expansion: • Deeper penet
Slide 16: Summary: the market leader in cardiopulmonary and sutureless valves
Summary: the market leader in cardiopulmonary and sutureless valves • Strong core business, significant market share • Life cycle management and new product Cardiopulmonary innovation enhances base business • Inorganic opportunities drive above-market growth • Superior new technology sutureless valv
Slide 17: LivaNova
LivaNova = ivaNova Health innovation that matters 17